• Home
  • Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).

Author List
Laura Ann Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark M. Moasser, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Pamela N. Munster, Michael J. Campbell, Lawrence Fong, Amy Jo Chien
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/420601074
Publication Year
2023
Publication Title
Laura Ann Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark M. Moasser, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Pamela N. Munster, Michael J. Campbell, Lawrence Fong, Amy Jo Chien. Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):1091-1091.